T³ – Technion Technology Transfer

T3 – Technion Technology Transfer is the commercialization arm of the Technion – Israel Institute of Technology, dedicated to transforming academic research into market-ready technologies. Based in Haifa, Israel, T3 manages the intellectual property portfolio of one of the world's leading science and engineering universities, facilitating licensing deals and the formation of startup companies. The organization plays a pivotal role in the life sciences sector, having birthed significant medical breakthroughs such as the Parkinson's drug Azilect and the cancer treatment technology TTFields. T3 provides comprehensive support to researchers, including patent prosecution, business development, and access to a global network of industrial partners and investors. By bridging the gap between the laboratory and the clinic, T3 accelerates the development of innovative therapies, medical devices, and digital health solutions. The office also oversees the Technion DRIVE Accelerator, fostering a new generation of deep-tech entrepreneurs.